(NASDAQ: AMGN) Amgen's forecast annual revenue growth rate of 3.76% is forecast to beat the US Drug Manufacturers - General industry's average forecast revenue growth rate of 2.73%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.31%.
Amgen's revenue in 2023 is $26,330,000,000.On average, 10 Wall Street analysts forecast AMGN's revenue for 2023 to be $14,615,921,132,494, with the lowest AMGN revenue forecast at $14,063,013,553,336, and the highest AMGN revenue forecast at $15,146,696,913,346. On average, 10 Wall Street analysts forecast AMGN's revenue for 2024 to be $15,394,936,635,249, with the lowest AMGN revenue forecast at $14,498,947,764,638, and the highest AMGN revenue forecast at $17,084,320,434,638.
In 2025, AMGN is forecast to generate $15,531,512,102,396 in revenue, with the lowest revenue forecast at $14,199,076,250,866 and the highest revenue forecast at $17,341,324,195,000.